Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Identifieur interne : 002989 ( Ncbi/Checkpoint ); précédent : 002988; suivant : 002990Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Auteurs : Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson ; Sarah Rose ; C Warren Olanow ; Peter JennerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (therapeutic use), Benzothiazoles (therapeutic use), Callithrix, Carbidopa (therapeutic use), Disability Evaluation, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Therapy, Combination (methods), Dyskinesias (drug therapy), Dyskinesias (etiology), Levodopa (therapeutic use), MPTP Poisoning (complications), Male, Motor Activity (drug effects), Time Factors.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Benzothiazoles, Carbidopa, Levodopa.
- complications : MPTP Poisoning.
- drug effects : Motor Activity.
- drug therapy : Dyskinesias.
- etiology : Dyskinesias.
- methods : Drug Therapy, Combination.
- Animals, Callithrix, Disability Evaluation, Disease Models, Animal, Dose-Response Relationship, Drug, Male, Time Factors.
Abstract
Reduced expression of dyskinesia is observed in levodopa-primed MPTP-treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D-2/D-3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non-dyskinetic MPTP-treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04-0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125-6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1-0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy.
DOI: 10.1002/mds.22960
PubMed: 20108359
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A13
- to stream PubMed, to step Curation: 001A13
- to stream PubMed, to step Checkpoint: 001696
- to stream Ncbi, to step Merge: 002989
- to stream Ncbi, to step Curation: 002989
Links to Exploration step
pubmed:20108359Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.</title><author><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><affiliation wicri:level="3"><nlm:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.22960</idno><idno type="RBID">pubmed:20108359</idno><idno type="pmid">20108359</idno><idno type="wicri:Area/PubMed/Corpus">001A13</idno><idno type="wicri:Area/PubMed/Curation">001A13</idno><idno type="wicri:Area/PubMed/Checkpoint">001696</idno><idno type="wicri:Area/Ncbi/Merge">002989</idno><idno type="wicri:Area/Ncbi/Curation">002989</idno><idno type="wicri:Area/Ncbi/Checkpoint">002989</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.</title><author><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><affiliation wicri:level="3"><nlm:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzothiazoles (therapeutic use)</term><term>Callithrix</term><term>Carbidopa (therapeutic use)</term><term>Disability Evaluation</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination (methods)</term><term>Dyskinesias (drug therapy)</term><term>Dyskinesias (etiology)</term><term>Levodopa (therapeutic use)</term><term>MPTP Poisoning (complications)</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Disability Evaluation</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Male</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Reduced expression of dyskinesia is observed in levodopa-primed MPTP-treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D-2/D-3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non-dyskinetic MPTP-treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04-0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125-6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1-0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J" last="Jackson">Michael J. Jackson</name><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A" last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002989 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002989 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:20108359
|texte= Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:20108359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |